Email updates

Keep up to date with the latest news and content from Infectious Agents and Cancer and BioMed Central.

Open Access Highly Accessed Review

Answering human papillomavirus vaccine concerns; a matter of science and time

David Hawkes1*, Candice E Lea2 and Matthew J Berryman3

Author Affiliations

1 The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria 3010, Australia

2 Research Centre for Injury Studies, Flinders University, Bedford Park, South Australia 5042, Australia

3 SMART Infrastructure Facility, University of Wollongong, New South Wales 2522, Australia

For all author emails, please log on.

Infectious Agents and Cancer 2013, 8:22  doi:10.1186/1750-9378-8-22

Published: 12 June 2013

Abstract

Since the introduction of the HPV vaccine, questions have been asked about its efficacy in preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have also been raised. This paper highlights the rapidly growing body of evidence (including clinical trials and post-marketing surveillance) illustrating both the safety of the HPV vaccine, through a detailed investigation of reported adverse events, and its efficacy in reducing both HPV infections rates and the resulting drop in cervical lesions, which have been demonstrated to be good predictors of cervical cancer risk.

Keywords:
Human papillomavirus; HPV; Safety; Cervical cancer; Cancer prevention; Adverse events; Clinical trials